- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 143273, 9 pages
http://dx.doi.org/10.1155/2013/143273
Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
1Medical Oncology, S. Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy
2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L'Aquila, Italy
3Radiology, S. Salvatore Hospital, 67100 L'Aquila, Italy
4Hepatobiliar-Pancreatic Surgery, S. Salvatore Hospital, 67100 L'Aquila, Italy
Received 26 June 2013; Revised 31 August 2013; Accepted 13 September 2013
Academic Editor: Hidekazu Kuramochi
Copyright © 2013 Gemma Bruera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Supplementary Material
Among Supplementary material, Table 1 describes KRAS mutations detected; Table 2 describes received dose-intensities; Table 3 describes toxicities characterizing limiting toxicity syndromes in individual patients; Table 4 describes activity, efficacy and effectiveness of FIr-B/FOx regimen according to KRAS genotype and extension of metastatic disease; Figure 1 reports progression-free survival and overall survival of KRAS wild-type patients (A) and KRAS mutant patients (B), liver-limited versus other/multiple metastatic disease.